(65 days)
Not Found
No
The device description clearly states it is a lateral flow immunochromatographic assay that can be performed without an instrument, indicating a simple chemical reaction and visual interpretation, not AI/ML.
No
This device is a diagnostic test for detecting phencyclidine in urine, not a device used for therapy or treatment.
Yes
Explanation: The device is described as "rapid chromatographic immunoassays for the qualitative detection of phencyclidine in human urine" and its intended use is to "selectively detect elevated levels of phencyclidine in urine". This indicates it is used to identify a specific substance in the body, which is a diagnostic function.
No
The device description clearly states it is a "rapid chromatographic immunoassay" and a "competitive binding, lateral flow immunochromatographic assay," which are physical test strips/devices that detect substances in urine. There is no mention of software as the primary or sole component.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it's for the "qualitative detection of phencyclidine in human urine." This involves testing a sample taken from the human body (in vitro) to gain information about a medical condition or state (presence of phencyclidine).
- Device Description: The description details a "rapid chromatographic immunoassay" that utilizes "antigen-antibody immunochemistry" to detect a substance in a "urine sample." This is a classic description of an in vitro diagnostic test.
- Performance Studies: The performance studies involve testing "clinical urine specimens" and comparing the results to other diagnostic methods (LifeSign Status DSTM PCP One-Step Phencyclidine Test and Gas Chromatography/Mass Spectrometry analysis). This further confirms its use in a diagnostic context.
N/A
Intended Use / Indications for Use
The ACON PCP One Step Phencyclidine Test Strip and ACON PCP One Step Phencyclidine Test Device are rapid chromatographic immunoassays for the qualitative detection of phencyclidine in human urine at a cut-off concentration of 25 ng/mL. They are intended for healthcare professionals including point of care sites.
Product codes (comma separated list FDA assigned to the subject device)
LCM
Device Description
The ACON PCP One Step Phencyclidine Test Strip and ACON PCP One Step Phencyclidine Test Device are competitive binding, lateral flow immunochromatographic assays for the qualitative Device are compoudive in a urine sample. The test is based on the principle of antigen-antibody immunochemistry. It utilizes the antibody to selectively detect elevated levels of phencyclidine in urine at a cut-off concentration of 25 ng/ml. These tests can be performed without the use of an instrument.
A drug-positive urine specimen will not generate a red-colored line in the designated test region, while a negative urine specimen will generate a red-colored line in the test region. To serve as a woredural control, a red-colored line will always appear at the control region if the test has been performed properly.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
healthcare professionals including point of care sites.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
A clinical evaluation was conducted using 212 clinical urine specimens which included 10% samples with the drug concentrations at -25% cutoff to +25% cutoff. This evaluation compared the test results of the ACON® PCP One Step Phencyclidine Test Strip and the Compared the tee term Phencyclidine Test Device against the LifeSign Status DSTM PCP One-Step Phencyclidine Test, as well as against the customary Gas Chromatography/Mass The comparisons of data obtained from this study yielded the Spectrometry analysis.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Accuracy
A clinical evaluation was conducted using 212 clinical urine specimens.
ACON PCP One Step Phencyclidine Test Strip versus the LifeSign Status DSTM PCP One-Step Phencyclidine Test:
Positive Agreement: 56 / 57 = 98% (91% - 100%)
Negative Agreement: 155 / 155 = 100% (98% - 100%)
Overall Agreement: 211 / 212 = 99.5% (97% - 100%*)
- 95% confidence intervals
ACON PCP One Step Phencyclidine Test Device versus the LifeSign Status DSTM PCP One-Step Phencyclidine Test:
Positive Agreement: 55 / 57 = 97% (88% - 100%)
Negative Agreement: 155 / 155 = 100% (98% - 100%)
Overall Agreement: 210 / 212 = 99% (97% - 100%*)
- 95% confidence intervals
ACON PCP One Step Phencyclidine Test Strip versus GC/MS at the cutoff of 25 ng/ml:
Positive agreement with GC/MS: 50 / 50 = 100%(93%-100%) *
Negative agreement with GC/MS: 156 / 162 = 96%(92% - 99%) *
Total agreement with GC/MS: 206 / 212 = 97%(94% - 99%) *
- 95% confidence intervals
ACON PCP One Step Phencyclidine Test Device versus GC/MS at the cutoff of 25 ng/ml:
Positive agreement with GC/MS: 50 / 50 = 100% (93%- 100%) *
Negative agreement with GC/MS: 157 / 162 = 97%(93% - 99%) *
Total agreement with GC/MS: 207 / 212 = 98%(94% - 99%) *
- 95% confidence intervals
These studies demonstrate the substantial equivalency between the ACON PCP One Step Phencyclidine Test Strip and ACON PCP One Step Phencyclidine Test Device and the LifeSign Status DSTM PCP One-Step Phencyclidine Test. It is also demonstrated that these rests are safe and effective in dececting phencyclidine at a concentration of 25 ng/mL. The POL study demonstrated that these tests are suitable for Health professionals including point-of-care sites.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
N/A
0
SUMMARY OF 510(k) SAFETY AND EFFECTIVENESS 8.
This summary of safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
The Assigned 510(k) number is: K011730
Submitter:
ACON Laboratories, Inc. 4108 Somento Valley Boulevard San Diego, California 92121
Tel.: 858-535-2030 Fax: 858-535-2038
Date: May 18, 2001
Contact Person: Edward Tung, Ph.D.
Product Names:
ACON® PCP One Step Phencyclidine Test Strip
ACON® PCP One Step Phencyclidine Test Device
Common Name:
Immunochromatographic test for the qualitative detection of phencyclidine in urine
Device Classification:
The ACON PCP One Step Phencyclidine Test Strip and ACON PCP One Step Phencyclidine Test Device are similar to other FDA-cleared devices for the qualitative detection of phencyclidine in urine specimens. These tests are used to provide a preliminary analytical result. (21 CFR 862) Phencyclidine test systems have been classified as Class II devices with moderate complexity.
Classification Name:
Phencyclidine test system
1
Intended Use:
The ACON® PCP One Step Phencyclidine Test Strip and ACON PCP One Step Phencyclidine Test The ACON TCT One Blep I helleyeusme rose of the qualitative detection of phencycliding in assacciared Device at a cut-off concentration of 25 ng/ml. They are intended for healthcare professionals including point of care sites.
Description:
Description.
The ACON PCP One Step Phencyclidine Test Strip and ACON PCP One Step Phencyclidine Test Device are competitive binding, lateral flow immunochromatographic assays for the qualitative Device are compoudive in a urine sample. The test is based on the principle of antigen-antibody immunochemistry. It utilizes the antibody to selectively detect elevated levels of phencyclidine in urine at a cut-off concentration of 25 ng/ml. These tests can be performed without the use of an instrument.
A drug-positive urine specimen will not generate a red-colored line in the designated test region, while a negative urine specimen will generate a red-colored line in the test region. To serve as a woredural control, a red-colored line will always appear at the control region if the test has been performed properly.
Predicate Device:
LifeSign Status DSTM PCP One-Step Phencyclidine Test
510(k) Number: K961266
Distributor: LifeSign, LLC 71 Veronica Avenue Somerset, New Jersey 08873
Comparison to a Predicate Device:
A comparison of the features of the ACON PCP One Step Phencyclidine Test Strip and ACON PCP One Step Phencyclidine Test Device versus the LifeSign Status DSTM PCP One-Step Phencyclidine Test is shown below:
- Both tests are assays intended for the qualitative detection of phencyclidine in urine . samples.
- Both tests are intended as a screening method that provides a preliminary analytical test . result.
- Both tests are immunochromatographic, lateral flow assays for the rapid detection of . phencyclidine with a visual, qualitative end result.
- Both tests utilize the same basic immunoassay principles that rely on antigen/ antibody . interactions to indicate a positive or negative result.
- Both tests have a cut-off phencyclidine concentration of 25 ng/ml. .
30
2
Safety and Effectiveness Data:
Accuracy
A clinical evaluation was conducted using 212 clinical urine specimens which included 10% samples with the drug concentrations at -25% cutoff to +25% cutoff. This evaluation compared the test results of the ACON® PCP One Step Phencyclidine Test Strip and the Compared the tee term Phencyclidine Test Device against the LifeSign Status DSTM PCP One-Step Phencyclidine Test, as well as against the customary Gas Chromatography/Mass The comparisons of data obtained from this study yielded the Spectrometry analysis. following results:
ACON PCP One Step Phencyclidine Test Strip versus the LifeSign Status DSTM PCP One-Step Phencyclidine Test:
Positive Agreement: 56 / 57 = 98% (91% - 100%) Negative Agreement: 155 / 155 = 100% (98% - 100%) Overall Agreement: 211 / 212 = 99.5% (97% - 100%*) * 95% confidence intervals
ACON PCP One Step Phencyclidine Test Device versus the LifeSign Status DSTM PCP One-Step Phencyclidine Test:
Positive Agreement: 55 / 57 = 97% (88% - 100%) Negative Agreement: 155 / 155 = 100% (98% - 100%) Overall Agreement: 210 / 212 = 99% (97% - 100%*) * 95% confidence intervals
ACON PCP One Step Phencyclidine Test Strip versus GC/MS at the cutoff of 25 ng/ml:
Positive agreement with GC/MS: 50 / 50 = 100%(93%-100%) * Negative agreement with GC/MS: 156 / 162 = 96%(92% - 99%) * Total agreement with GC/MS: 206 / 212 = 97%(94% - 99%) * * 95% confidence intervals
ACON PCP One Step Phencyclidine Test Device versus GC/MS at the cutoff of 25 ng/ml:
Positive agreement with GC/MS: 50 / 50 = 100% (93%- 100%) * Negative agreement with GC/MS: 157 / 162 = 97%(93% - 99%) * Total agreement with GC/MS: 207 / 212 = 98%(94% - 99%) * * 95% confidence intervals
Conclusion:
These studies demonstrate the substantial equivalency between the ACON PCP One Step Phencyclidine Test Strip and ACON PCP One Step Phencyclidine Test Device and the LifeSign Status DSTM PCP One-Step Phencyclidine Test, which has already being marketed in the United States. It is also demonstrated that these rests are safe and effective in dececting phencyclidine at a concentration of 25 ng/mL. The POL study demonstrated that these tests are suitable for Health professionals including point-of-care sites.
3
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized image of three wavy lines, which are meant to represent the human form.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
AUG - 9 2001
Edward Tung, Ph.D. Director of Regulatory Affairs ACON Laboratories, Inc. 4108 Sorrento Valley Blvd. San Diego, CA 92121
Re: 510(k) Number: K011730 Trade/Device Name: ACON® PCP One Step Phencyclidine Test Strip and ACON® PCP One Step Phencyclidine Test Device
Regulatory Class: II Product Code: LCM Dated: June 1, 2001 Received: June 5, 2001
Dear Dr. Tung:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: General (GMP) regulation (21 CFR Part 820) and that, through periodic GMP inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
4
Page 2 -
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and v additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Autman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
INDICATIONS FOR USE 10.
K011730 510(k) Number:
Device Name: ACON® PCP One Step Phencyclidine Test Strip
ACON® PCP One Step Phencyclidine Test Device
Indications for Use:
The ACON PCP One Step Phencyclidine Test Strip and ACON PCP One Step Phencyclidine Test Device are rapid chromatographic immunoassays for the qualitative detection of phencyclidine in human urine at a cut-off concentration of 25 ng/mL. They are intended for healthcare professionals including point of care sites.
(Division Sign-Off)
Division of Clinical
510(k) Numbe K11730
(Please do not write below this point)
Concurrence of CDRH, Office of Device Evaluation (ODE)
| Prescription Use | ✓ | Or | Over-The-Counter Use ______ |
|---|---|---|---|
| (Per 21 CFR 801.109) |
| Kesia Alexander for John Cooper | |
|---|---|
| (Division Sign-Off) | |
| Division of Clinical Laboratory Devices | |
| 510(k) Number | K011730 |